You are here

Home » Content

AKUT MYELOİD LÖSEMİDE STANDART TEDAVİ PROTOKOLÜ İLE SAĞLANAN KOMPLET REMİSYON ORANI VE BU ORANI ETKİLEYEN FAKTÖRLER

Journal Name:

  • İstanbul Tıp Fakültesi Dergisi

Publication Year:

  • 2002

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Complete remission rates andfactors that influence the complete remission rates with Standard therapy protocols in acute myeloid leukemia. Complete remission (CR) induction rates achieved by Standard remission-induction protocols including cytosine arabinoside (Ara-c) and anthracyclines (daunorubicine or idarubicine) have been reported to be 60-70% in acute myeloid leukemia (AML). We evaluated the CR rates and factors that influence the rates which were obtained by Standard remission-induction protocols in our hematology clinic. The number of the patients studied was 218 and their ages ranged from 16 to 73. CR was achieved in 156 patients (71.6%). Thirty four patients (15.6%) were unresponsive, and 28 patients died in the first month of treatment. CR was achieved in 117 patients (75%) with one course of tre-atment and in 39 patients (25%) with two courses. Daunorubicine (DNR) was used in 169 patients (77.5%) and idarubicine (IDA) in 49 (22.5%) as anthracycline. CR was 70.4% with DNR and 75.5% with IDA. CR rates were inversely correlated with the presence of splenome-galy, high leukocyte counts, high LDH levels and findings of dishematopoiesis. In conclusion our CR rates in patients with AML were compatible with results reported
Bookmark/Search this post with
Abstract (Original Language): 
Sitozin-arabinozid ve antrasiklinden (daunorubisin veya idarubisin) oluşan standart remisyon-indiiksiyon tedavi protokolleri ile akut myeloid lösemide (AML), %60-70 oranında komplet remisyon bildirilmektedir. Bu çalışmada, Hematoloji servisimizde yatan erişkin AML'li hastalarda, standart remisyon-indüksiyon tedavisi ile elde edilen komplet remisyon oranı ve bu oran üzerine etkili faktörler değerlendirildi. Yaşları 16-73 arasında değişen 218 hasta çalışmaya alındı. Standart remisyon indüksiyon tedavisi ile 156 (%71.6) hastada komplet remisyon elde edildi. 34 hasta (%15.6) tedaviye cevapsız iken, 28 hastada (%12.8) tedavinin ilk ayında ölüm görüldü. Komplet remisyon sağlanan olguların 117'sinde (%75) bir kür, 39'unda (%25) ise iki kür standart tedavi ile komplet remisyon sağlandı. Standart remisyon-indüksiyon tedavisinde, 169 olguya (%77.5) daunorubisin (DNR), 49 olguya (%22.5) ise idarubisin (IDA) uygulanmıştır. DNR uygulanan olgularda komplet remisyon oranı %70.4 iken, IDA uygulanan olgularda %75.5 bulunmuştur. Her iki grup karşılaştırıldığında, komplet remisyon sağlama açısından istatistiksel fark bulunmadı (p=0.46). Splenomegali varlığı, tedavi öncesi lökosit sayısı ve Laktik dehidrogenaz (LDH) düzeyinin yüksek olması, kemik iliğinde dishematopoez bulgularının olması komplet remisyon oranını azaltan faktörler olarak bulundu. Sonuç olarak, erişkin AML'li hastalarda elde ettiğimiz komplet remisyon oranı, dünya standartları ölçüsündedir ve bu tedavi protokolleri standart tedavi olarak uygulanmaya devam etmektedir.
FULL TEXT (PDF): 
PDF icon arastirmax-akut-myeloid-losemide-standart-tedavi-protokolu-ile-saglanan-komplet-remisyon-orani-bu-orani-etkileyen-faktorler.pdf
  • 3
182-187
  • Turkish

REFERENCES

References: 

1. Baudard M, Marie J, Cadiou M, et al.: Acute myelogeno-us leukemia in the elderly: prospective study of 235 con-secutive patients. Br J Haematol 86:82 (1994).
2. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C.: Proposed revised criteria for the classifacation of acute myeloid leukemia: a report of the French-American-British Cooperative group. Ann InternMed 103:620(1985).
3. Berman E, Heller G, Santorsa J, McKanzie S, Gee T, Kempin S, Gulati S, Andreff M, Kolitz J, Gabrilove J.: Results of a randomized trial comparing idarubicin and cytosine arabinoside with dauonorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 77:1666 (1991).
4. Bow EJ, Kilpatrick MG, Scott BA, Clinch JJ, Cheang MS.: Acute myeloid leukemia in Manitoba. The conse-quences of Standard "7+3" remission-induction therapy followed by high dose cytarabine postremission consoli-dation for myelosuppresion, infectious morbidity and outcome. Cancer 74:52 (1994).
5. Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD, Brunning R, Gale RP, Grever MR, Keating MJ.: Report of the National Cancer Institu-te-sponsored vvorkshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 8:813 (1990).
6. Estey EH.: Treatment of relapsed and refractory acute myelogenous leukemia. Leukemia 14:476 (2000).
7. Ferrara F, Mirto S.: Serum LDH value as a predictor of clinical outcome in acute myelogenous leukemia in the elderly. Br J Haematol 92:627 (1996).
8. Herzig RH, Lazarus HM, Wolff SN, Phillips GL, Herzig GP.: High-dose cytosine arabinoside therapy with or wit-hout anthracycline antibiotics for remission reinduction
of acute nonlymphoblastic leukemia. J Clin Oncol 3:992 (1985).
9. Hug V, Keating M, McCredie K, et al.: Clinical course and response to treatment of patients with acute myelogenous leukemia presenting with a high leukocyte count. Cancer 52:773 (1983).
10. Passe S, Mike V, Mertelsmann R, et al.: Acute nonly-mphocytic Leukemia: Prognostic factors in adults with long-term follow up. Cancer 50:1462 (1982).
11. Rai KR, Holland JF, Glidevvell OJ, Glidevvell OJ, Wein-berg G, Brunner K, Obrecht JP, Preisler HD, Nawabi IW, Prager D, Carey M.: Treatment of acute myelocytic leukemia: A study by Cancer and Leukemia Group B. Blood 58:1203 (1981).
12. Rees JKH.: Chemotherapy of acute leukemia in UK: past, present and future. Bone Marrow Transplant 4:110 (1989).
13. Schvvartz RS, Mackintosh R, Hatpern J, et al.: Muldvari-ate analysis of factors associated with outcome of treatment for adults vvith acute myelogenous leukemia. Cancer 54:1672(1984).
14. Stein AS, O'Donnell MR, Slovak ML, Nademanee A, Dagis A, Schmidt GM, Parker PM, Snyder DS, Smith EP, Somlo G, Margolin KA, Nademanee A, Dagis A, Schmidt GM, Parker PM, Snyder DS, Smith EP, Somlo G, Margolin KA.: High-dose cytosine arabinoside and dauonorubisin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: impact of cytogenetics on achieving a complete remission. Leukemia 14:1191 (2000).
15. Vogler WR, Velez-Garcia R, Weiner RS, et al.: A phase III trial comparing idarubicin and dauonorubicin in acute myelogenous leukemia: a Southeastern Cancer Study Group study. J Clin Oncol 10:1103 (1992).
16. Wiernik PH, Banks PLC, Case Jr DC, et al: Cytarabine plus idarubicin or dauonorubicin as induction and conso-lidation therapyfor previously untreated adult patients with acute myeloid leukemia. Blood 79:313 (1992).
17. Yates J, Glidewell O, Wiernik P, Cooper MR, Steinberg D, Dosik H, Levy R, Hoagland C, Henry P, Gottlieb A, Cornell C, Berenberg J, Hutchison JL, Raich P, Nissen N, Ellison RR, Frelick R, James GW, Falkson G, Silver RT, Haurani F, Green M, Henderson E, Leone L, Holland JF.: Cytosine arabinoside vvith daunorubicin or adri-amycin for therapy of acute myelocytic leukemia: a CALGB study. Blood 60:454 (1982).

Thank you for copying data from http://www.arastirmax.com